<DOC>
	<DOCNO>NCT00019448</DOCNO>
	<brief_summary>RATIONALE : Vaccines make DNA may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . Combining vaccine therapy interleukin-2 may kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine therapy without interleukin-2 treating patient metastatic melanoma respond previous treatment .</brief_summary>
	<brief_title>Vaccine Therapy With Without Interleukin-2 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine clinical response patient receive DNA gp100 antigen alone combination interleukin-2 recurrent metastatic melanoma . II . Identify immunologic response patient prior treatment . III . Determine toxicity treatment patient . PROTOCOL OUTLINE : Patients accrue first three cohort study proceeds final two cohort response observe . Cohort I : Patients receive gp100 antigen intramuscularly ( IM ) 2 proximal extremity every 4 week 4 dos . ( Closed December , 1999 ) Cohort II : Patients receive gp100 antigen intradermally ( ID ) 5 site 2 proximal extremity every 4 week 4 dos . ( Closed December , 1999 ) Cohort III : Patients receive gp100 antigen IM 2 proximal extremity every 4 week 4 dos . If patient exhibit immunologic response dose-limiting toxicity , may receive high dose gp100 antigen subsequent course . Cohort IV : If cohort I , II , III produce immune response experience dose-limiting toxicity , patient receive high dose gp100 antigen IM 2 proximal extremity every 4 week 4 dos . Cohort V : Patients receive gp100 antigen IM ID dose find produce immunization every 4 week 4 dos . Patients also receive interleukin-2 IV 15 minute every 8 hour 5 day ( 15 dos ) , begin within 24 hour gp100 antigen . Patients minor , mixed , partial response stable disease may receive additional course treatment follow 3-4 week rest . Patients receive maximum 12 course . Patients follow 4-6 week . PROJECTED ACCRUAL : A maximum 65 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis metastatic melanoma fail standard therapy Measurable disease Prior/Concurrent Therapy Biologic therapy : At least 3 week since prior biologic therapy Chemotherapy : At least 3 week since prior chemotherapy Endocrine therapy : At least 3 week since prior endocrine therapy No concurrent steroid therapy Radiotherapy : At least 3 week since prior radiotherapy Surgery : Prior surgery allow Patient Characteristics Age : 16 Performance status : ECOG 0 1 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Platelet count least 90,000/mm3 No coagulation disorder Hepatic : Bilirubin great 1.6 mg/dL ALT/AST le 2 time normal Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No major cardiovascular disease Pulmonary : No major respiratory disease Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No active systemic infection No autoimmune disease No primary secondary immunodeficiency HIV negative</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>skin tumor</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage , melanoma</keyword>
</DOC>